Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | DDX3X | O00571 | 2/20 | 0.48 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9313156 | 0.84 | TDP1 (0.67) | ALDH1A1TDP1LMNAMEN1KMT2A | |
| SCHEMBL7249243 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TDP1LMNAMEN1GAA | |
| SCHEMBL29922510 | 0.83 | MEN1 (0.48) | ALDH1A1TDP1LMNAMEN1GAA | |
| SCHEMBL21800089 | 0.83 | MEN1 (0.48) | ALDH1A1TDP1LMNAMEN1GAA | |
| SCHEMBL6225932 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TDP1LMNAMEN1GAA | |
| SCHEMBL22417483 | 0.82 | MAOB (0.53) | ALDH1A1TDP1MEN1GAAKMT2A | |
| SCHEMBL21799928 | 0.80 | MEN1 (0.46) | ALDH1A1TDP1LMNAMEN1GAA | |
| SCHEMBL29922411 | 0.80 | MEN1 (0.46) | ALDH1A1TDP1LMNAMEN1GAA | |
| SCHEMBL11765238 | 0.80 | ALDH1A1 (0.55) | ALDH1A1TDP1LMNAMEN1GAA | |
| SCHEMBL21799475 | 0.79 | ALDH1A1 (0.54) | ALDH1A1TDP1LMNAMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894884-A | Trifunctional organic catalyst, and preparation method and application thereof | 浙江大学 | 2023-04-04 | — | — | CN | claimed |
| US-4530728-A | Shrinkage inhibition | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1985-07-23 | — | — | US | claimed |
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-115894884-A | Trifunctional organic catalyst, and preparation method and application thereof | 浙江大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-110603273-B | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220220106-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2022-07-14 | — | — | US | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-20210178336-A1 | SELECTIVELY PERMEABLE GRAPHENE OXIDE MEMBRANE | NITTO DENKO CORPORATION (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20210032202-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD. (SG) | 2021-02-04 | — | — | US | disclosed |
| WO-2020216350-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2020-10-29 | — | — | WO | disclosed |
| US-20090023929-A1 | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same | SANKYO COMPANY, LIMITED (JP) | 2009-01-22 | — | — | US | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| CN-101068770-A | Process for producing 6-substituted-1-methyl-1-H-benzimidazole derivative and synthetic intermediate therefor | SANKYO CO (JP) | 2007-11-07 | — | — | CN | disclosed |
| EP-1798216-A1 | INTERMEDIATE OF 6-SUBSTITUTED-1-METHYL-1-H-BENZIMIDAZOLE DERIVATIVE AND METHOD FOR PRODUCING SAME | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| EP-0188337-A2 | Thermosettable heat-resistant epoxy resin composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-07-23 | — | — | EP | disclosed |
| US-4530728-A | Shrinkage inhibition | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1985-07-23 | — | — | US | disclosed |
| US-4530728-A | Shrinkage inhibition | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1985-07-23 | — | — | US | disclosed |
| US-4441942-A | HIGH PEEL STRENGTH | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | ALDH1A1 2834/4885TDP1 4830/4885LMNA 4645/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | ALDH1A1 1867/4885TDP1 3111/4885LMNA 4844/4885 |
| US-20210032202-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | ALDH1A1 526/4885TDP1 1979/4885LMNA 2626/4885 |
| US-20090023929-A1 | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same | AZI2, CYC1, CCNI | ALDH1A1 928/4885TDP1 2994/4885LMNA 1690/4885 |
| US-20220220106-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | MTOR, RICTOR, EIF4E | ALDH1A1 4720/4885TDP1 4643/4885LMNA 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.